Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$10.36 USD
+0.01 (0.10%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $10.37 +0.01 (0.10%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CDMO 10.36 +0.01(0.10%)
Will CDMO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CDMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDMO
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
CDMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
Other News for CDMO
Biotech Alert: Searches spiking for these stocks today
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
Biotech Alert: Searches spiking for these stocks today
Avid Bioservices stock rallies 18% after reporting increased backlog
Avid Bioservices price target raised by $4 at RBC Capital, here's why